© Copyright 2001-2023 Erowid Center. DrugsData is a project of
Erowid Center. All rights reserved.
By using this site you agree not to publish its images, data, results, or analysis of its results without written permission from Erowid Center.
Permission is required before using data from DrugsData in any of these ways, including importing it into public or shared databases, software, or systems.
This policy has been in place since 2001 in order to require cooperation and credit by researchers and app authors.
Your javascript is turned off.
To remove this message, turn on javascript and accept the Terms of Use.
Unidentified Substance #2: 20 parts (since identified as 2'-Fluoro-2-oxo-PCE after first being misidentified as 3'-Fluoro-2-oxo-PCE)
All samples analyzed by the DrugsData lab prior to early 2023 that were reported as containing Fluorexetamine have been reexamined in comparison to this new standard. They have all been retroactively revised; they all contain 2-Fluoro-2-oxo PCE, including this sample. To date, no samples tested by DrugsData have contained 3-Fluoro-2-oxo PCE.
Dec 20 2022: The secondary unidentified may be a positional isomer of the more abundant one. (thank you, Y.)
May 5 2022: Fluorexetamine has been confirmed by comparison to certified reference standard.
Apr 22 2022: Unidentified substance has been tentatively identified as Fluorextamine with the second chemical likely the hydroxylimine variant of the parent compound (thank you, K.). We are working to finalize this identification.